MARKET

HTGM

HTGM

HTG Molecular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.540
-0.020
-0.56%
Closed 16:00 05/17 EDT
OPEN
3.540
PREV CLOSE
3.560
HIGH
3.698
LOW
3.500
VOLUME
32.32K
TURNOVER
--
52 WEEK HIGH
13.80
52 WEEK LOW
3.500
MARKET CAP
22.00M
P/E (TTM)
-0.8664
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 3d ago
--HC Wainwright Adjusts HTG Molecular Diagnostics' Price Target to $9 From $11, Keeps Buy Rating
MT Newswires · 3d ago
SVB Leerink Maintains Outperform on HTG Molecular Diagnostics, Lowers Price Target to $10
SVB Leerink analyst Puneet Souda maintains HTG Molecular Diagnostics (NASDAQ:HTGM) with a Outperform and lowers the price target from $15 to $10.
Benzinga · 3d ago
--SVB Leerink Adjusts HTG Molecular Diagnostics PT to $10 From $15, Maintains Outperform Rating
MT Newswires · 3d ago
Recap: HTG Molecular Diagnostics Q1 Earnings
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) were flat after the company reported Q1 results. Quarterly Results Earnings per share were down 900.00% over the past year to ($0.80), which beat the estimate of ($1.02).
Benzinga · 4d ago
HTG Molecular EPS beats by $0.18, beats on revenue
HTG Molecular (HTGM): Q1 GAAP EPS of -$0.80 beats by $0.18.Revenue of $1.44M (-35.4% Y/Y) beats by $0.04M.Cash, cash equivalents and short-term available-for-sale securities totaled $30.8 million as of March
Seekingalpha · 4d ago
HTG Molecular Diagnostics Reports First Quarter 2021 Results and Provides a Corporate Update
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2021.
GlobeNewswire · 4d ago
HTG Molecular Diagnostics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HTGM. Analyze the recent business situations of HTG Molecular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HTGM stock price target is 12.50 with a high estimate of 15.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 7.15M
% Owned: 115.02%
Shares Outstanding: 6.21M
TypeInstitutionsShares
Increased
6
199.30K
New
2
232.03K
Decreased
2
4.56K
Sold Out
4
57.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.90%
Healthcare Equipment & Supplies
-0.70%
Key Executives
President/Chief Executive Officer/Director
John Lubniewski
Chief Financial Officer/Senior Vice President/Treasurer/Secretary
Shaun McMeans
Senior Vice President
Byron Lawson
Lead Director/Independent Director
Ann Hanham
Independent Director
Harry George
Independent Director
Michelle Griffin
Independent Director
Donnie Hardison
Independent Director
James LaFrance
Independent Director
Lee McCracken
No Data
About HTGM
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Webull offers kinds of HTG Molecular Diagnostics Inc stock information, including NASDAQ:HTGM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTGM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HTGM stock methods without spending real money on the virtual paper trading platform.